What is the latest TORNTPHARM stock price?
The latest stored price for TORNTPHARM is Rs 4,896.50 as of 2026-08-21.
gimli
TORNTPHARM stock AI analysis
TORNTPHARM Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
TORRENT PHARMACEUTICALS L is a large-cap stock in Healthcare. This Gimli page shows the latest available TORNTPHARM price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹4,896.50
1W return
+1.31%
1M return
-2.86%
3M return
+9.56%
6M return
+15.44%
1Y return
+34.25%
Market cap
₹165,719.79 cr
PE
75.98
PB
9.42
ROE
+17.33%
ROCE
+16.13%
RSI
48.73
Turnover
₹110.79 cr
Why it can matter in screens
- Momentum: TORNTPHARM is above 50DMA, above 200DMA; RSI is 48.73.
- Returns: 1D -2.17%, 1W +1.31%, 1M -2.86%, 3M +9.56%, 1Y +34.25%.
- Trend levels: 52W high ₹5,250.00, 52W low ₹4,240.30, off high -6.73%.
- Liquidity: latest turnover is ₹110.79 cr; volume vs 20D is +0.44%.
- Valuation/profitability: PE 75.98, PB 9.42, ROE +17.33%, ROCE +16.13%.
- Growth: 3Y sales CAGR +13.27%, 3Y profit CAGR +20.21%.
Quick Answers
Is TORNTPHARM above its 50DMA and 200DMA?
TORNTPHARM is above 50DMA, above 200DMA. The latest 50DMA is 4,826.64 and the latest 200DMA is 4,267.99.
What are TORNTPHARM PE, ROE and ROCE?
TORNTPHARM has PE 75.98, ROE +17.33%, and ROCE +16.13% in Gimli's latest available snapshot.
How has TORNTPHARM performed recently?
TORNTPHARM has returned -2.86% over 1 month, +9.56% over 3 months, and +34.25% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 4,835.00 cr | 1,631.00 cr | 566.00 cr | 14.87 |
| 2026-03-31 | 4,128.00 cr | 1,273.00 cr | 389.00 cr | 11.51 |
| 2025-12-31 | 3,251.00 cr | 1,065.00 cr | 635.00 cr | 18.77 |
| 2025-09-30 | 3,246.00 cr | 1,043.00 cr | 591.00 cr | 17.45 |
| 2025-06-30 | 3,128.00 cr | 995.00 cr | 548.00 cr | 16.19 |
| 2025-03-31 | 2,909.00 cr | 922.00 cr | 498.00 cr | 14.71 |
| 2024-12-31 | 2,762.00 cr | 947.00 cr | 503.00 cr | 14.88 |
| 2024-09-30 | 2,831.00 cr | 923.00 cr | n/a | 13.37 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 13,752.99 cr | 4,375.75 cr | 2,163.37 cr | 64.75 |
| 2025-03-31 | 11,317.25 cr | 3,719.12 cr | 1,911.25 cr | 56.47 |
| 2024-03-31 | 10,562.31 cr | 3,500.04 cr | 1,656.38 cr | 48.94 |
| 2023-03-31 | 9,463.69 cr | 2,881.43 cr | 1,245.23 cr | 36.79 |
| 2022-03-31 | 6,946.49 cr | 2,140.77 cr | 991.45 cr | 22.96 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 44,311.96 cr | 1,117.20 cr | 15,025.50 cr | 17,584.83 cr |
| 2025-03-31 | 14,989.74 cr | 573.48 cr | 3,202.32 cr | 7,590.69 cr |
| 2024-03-31 | 15,060.58 cr | 835.14 cr | 4,021.94 cr | 6,856.15 cr |
| 2023-03-31 | 15,011.85 cr | 508.53 cr | 5,368.56 cr | 6,198.07 cr |
| 2022-03-31 | 13,099.84 cr | 398.40 cr | 4,069.65 cr | 5,952.95 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 3,022.71 cr | 2,345.32 cr | n/a |
| 2025-03-31 | 2,585.11 cr | 1,973.24 cr | n/a |
| 2024-03-31 | 3,266.08 cr | 2,833.30 cr | n/a |
| 2023-03-31 | 2,368.13 cr | 1,794.19 cr | n/a |
| 2022-03-31 | 1,802.99 cr | 1,600.42 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-07-20 | +60.78% | +17.97% | +12.87% | +8.27% | +8.38% | +0.00% |
| 2026-06-30 | +68.31% | +15.44% | +9.83% | +4.94% | +6.42% | +0.00% |
| 2026-03-31 | +68.31% | +16.18% | +9.06% | +4.45% | +6.45% | +0.00% |
| 2025-12-31 | +68.31% | +16.13% | +9.14% | +4.83% | +6.42% | +0.00% |
| 2025-09-30 | +68.31% | +15.92% | +9.28% | +5.12% | +6.49% | +0.00% |
| 2025-06-30 | +68.31% | +16.09% | +8.65% | +4.95% | +6.94% | +0.00% |
| 2025-03-31 | +68.31% | +16.31% | +8.35% | +5.03% | +7.03% | +0.00% |
| 2024-12-31 | +68.31% | +16.17% | +8.35% | +4.88% | +7.17% | +0.00% |
| 2024-09-30 | +71.25% | +14.46% | +7.08% | +3.69% | +7.21% | +0.00% |
| 2024-06-30 | +71.25% | +14.22% | +7.27% | +4.35% | +7.26% | +0.00% |
| 2024-03-31 | +71.25% | +14.14% | +7.26% | +4.46% | +7.36% | +0.00% |
| 2023-12-31 | +71.25% | +14.09% | +7.21% | +4.48% | +7.45% | +0.00% |
| 2023-09-30 | +71.25% | +13.15% | +8.00% | +5.32% | +7.60% | +0.00% |
| 2023-06-30 | +71.25% | +12.84% | +8.31% | +5.59% | +7.60% | +0.00% |
| 2023-03-31 | +71.25% | +12.04% | +9.00% | +6.37% | +7.71% | +0.00% |
| 2022-12-31 | +71.25% | +12.09% | +8.87% | +6.23% | +7.80% | +0.00% |
| 2022-09-30 | +71.25% | +11.37% | +9.51% | +6.72% | +7.88% | +0.00% |
| 2022-07-13 | +71.25% | +0.00% | +20.87% | n/a | n/a | +0.00% |
| 2022-06-30 | +71.25% | +0.00% | +20.81% | n/a | n/a | +0.00% |
| 2022-03-31 | +71.25% | +0.00% | +20.62% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
| DRREDDY | DR. REDDY S LABORATORIES | 97,804.91 cr | 29.535819 | +9.23% | -7.98% |
Try these prompts
- Analyze TORRENT PHARMACEUTICALS L with valuation, momentum and industry peers
- Compare TORNTPHARM with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare TORNTPHARM with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.